Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.62 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7887532 | 0.99 | ALDH1A1 (0.74) | ALDH1A1KDM4ESMN1; SMN2GAANPC1 | |
| SCHEMBL1242965 | 0.93 | HRH3 (0.70) | ALDH1A1KDM4ESMN1; SMN2GAAHRH3 | |
| SCHEMBL14714478 | 0.89 | HRH3 (0.77) | ALDH1A1KDM4ESMN1; SMN2GAANPC1 | |
| SCHEMBL3366608 | 0.87 | LTA4H (0.78) | ALDH1A1KDM4ESMN1; SMN2GAANPC1 | |
| SCHEMBL4455251 | 0.87 | ALDH1A1 (0.92) | ALDH1A1KDM4ESMN1; SMN2GAAPSMB1 | |
| SCHEMBL3007594 | 0.87 | GAA (0.71) | ALDH1A1KDM4ESMN1; SMN2GAANPC1 | |
| SCHEMBL990939 | 0.87 | GAA (0.71) | ALDH1A1KDM4ESMN1; SMN2GAANPC1 | |
| Hydrochloric Acid SCHEMBL9337271 | 0.87 | ALDH1A1 (0.60) | ALDH1A1KDM4ESMN1; SMN2GAANPC1 | |
| Methylparaben SCHEMBL6219419 | 0.87 | KDM4E (0.63) | ALDH1A1KDM4ESMN1; SMN2GAANPC1 | |
| SCHEMBL6442924 | 0.86 | PSMB1 (0.77) | ALDH1A1KDM4ELTA4HPSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999012532-A2 | PIPERIDINE DERIVATIVES AGAINST MALARIA | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-18 | — | — | WO | claimed |
| US-20250051296-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-02-13 | — | — | US | disclosed |
| US-12103917-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20230002394-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210214362-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2021-07-15 | — | — | US | disclosed |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-06-08 | — | — | US | disclosed |
| WO-1999012532-A2 | PIPERIDINE DERIVATIVES AGAINST MALARIA | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-18 | — | — | WO | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| EP-0410358-B1 | AROMATIC CARBOXYLIC ACID AMIDES, THEIR PREPARATION AND THEIR USE AS MEDICINES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-09-29 | — | — | EP | disclosed |
| US-5216153-A | Therapy and prophylaxis for skin, autoimmune and rheumatic diseases | HOFFMANN-LA ROCHE INC. (US) | 1993-06-01 | — | — | US | disclosed |
| US-5128470-A | Aantiinflammatory, antiallergens | HOFFMANN-LA ROCHE INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0410358-A1 | Aromatic carboxylic acid amides, their preparation and their use as medicines | F. HOFFMANN-LA ROCHE AG (CH) | 1991-01-30 | — | — | EP | disclosed |
| EP-0062504-B1 | PROCESS FOR PREPARING 3-(4-AMINOETHOXYBENZOYL)BENZO(B)THIOPHENES | ELI LILLY AND COMPANY (US) | 1986-01-02 | — | — | EP | disclosed |
| US-4358593-A | BY ACYLATION OF PROTECTED 6-HYDROXY,2-(4-HYDROXYPHENYL) BENZO (B)THIOPHENE USING A FRIEDEL CRAFTS CATALYSTS; HYDROLYSIS | ELI LILLY AND COMPANY (US) | 1982-11-09 | — | — | US | disclosed |
| EP-0062504-A1 | Process for preparing 3-(4-aminoethoxybenzoyl)benzo(b)thiophenes | ELI LILLY AND COMPANY (US) | 1982-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051296-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | ALDH1A1 3918/4885KDM4E 3722/4885SMN1; SMN2 205/4885 |
| US-20230002394-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | ALDH1A1 1592/4885KDM4E 3393/4885SMN1; SMN2 61/4885 |
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | ALDH1A1 3918/4885KDM4E 3722/4885SMN1; SMN2 205/4885 |
| US-20210214362-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | ALDH1A1 1592/4885KDM4E 3393/4885SMN1; SMN2 61/4885 |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | ALDH1A1 1592/4885KDM4E 3393/4885SMN1; SMN2 61/4885 |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | MYC, MYCBP, MLYCD | ALDH1A1 3918/4885KDM4E 3722/4885SMN1; SMN2 205/4885 |
| US-12103917-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | MYC, MYCBP, MLYCD | ALDH1A1 3918/4885KDM4E 3722/4885SMN1; SMN2 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.